| # | Drug | Count |
|---|---|---|
| 0 | PANTOPRAZOLE | 26 |
| 1 | CARVEDILOL | 23 |
| 2 | FUROSEMIDE | 22 |
| 3 | DOXAZOSIN MESYLATE | 21 |
| 4 | TACROLIMUS | 21 |
| 5 | TORSEMIDE | 21 |
| 6 | DARBEPOETIN ALFA | 20 |
| 7 | FLUVASTATIN | 20 |
| 8 | SODIUM BICARBONATE | 20 |
| 9 | SODIUM BICARBONATE INJECTION, | 20 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | CHENODIOL | 1 | 0.0028 |
| 1 | FLUVASTATIN SODIUM | 11 | 0.0025 |
| 2 | AMPHOTERICIN B | 19 | 0.0015 |
| 3 | ONASEMNOGENE ABEPARVOVEC-XIOI | 3 | 0.0013 |
| 4 | ELIGLUSTAT | 2 | 0.0012 |
| 5 | VALGANCICLOVIR | 20 | 0.0010 |
| 6 | PIRTOBRUTINIB | 1 | 0.0010 |
| 7 | HUMAN IMMUNOGLOBULIN G | 18 | 0.0009 |
| 8 | SODIUM BICARBONATE INJECTION, | 20 | 0.0008 |
| 9 | AZILSARTAN KAMEDOXOMIL AND CHLORTHALIDONE | 1 | 0.0008 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Lipid-based Polyene Antifungal [EPC] | 19 | 0.0015 |
| 1 | Human Immunoglobulin G [EPC] | 24 | 0.0011 |
| 2 | Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor [EPC] | 20 | 0.0009 |
| 3 | Glucosylceramide Synthase Inhibitor [EPC] | 2 | 0.0007 |
| 4 | Polyene Antifungal [EPC] | 20 | 0.0005 |
| 5 | Radioligand Therapeutic Agent [EPC] | 6 | 0.0004 |
| 6 | SARS-CoV-2 Nucleotide Analog RNA Polymerase Inhibitor [EPC] | 5 | 0.0004 |
| 7 | Erythropoiesis-stimulating Agent [EPC] | 20 | 0.0004 |
| 8 | Interleukin-17A Antagonist [EPC] | 12 | 0.0003 |
| 9 | Survival of Motor Neuron 2 Splicing Modifier [EPC] | 1 | 0.0002 |